Premium
Analysis and Quantitation of the β‐Amyloid Precursor Protein in the Cerebrospinal Fluid of Alzheimer's Disease Patients with a Monoclonal Antibody‐Based Immunoassay
Author(s) -
Henriksson Thomas,
Barbour Robin M.,
Braa Sonia,
Ward Pamela,
Fritz Lawrence C.,
JohnsonWood Kelly,
Chung Hyung D.,
Burke William,
Reinikainen Kari J.,
Riekkinen Paavo,
Schenk Dale B.
Publication year - 1991
Publication title -
journal of neurochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.75
H-Index - 229
eISSN - 1471-4159
pISSN - 0022-3042
DOI - 10.1111/j.1471-4159.1991.tb02026.x
Subject(s) - immunoassay , cerebrospinal fluid , monoclonal antibody , amyloid precursor protein , alzheimer's disease , antibody , monoclonal , amyloid (mycology) , pathology , microbiology and biotechnology , chemistry , disease , medicine , immunology , biology
One of the major clinical findings in Alzheimer's disease (AD) is the formation of deposits of β‐amyloid protein in amyloid plaques, derived from the β‐amyloid precursor protein (β‐APP). To determine the possible use of β‐APP as a diagnostic marker for AD in CSF, a monoclonal antibody‐based immunoassay specific for this protein was developed. The assay does not differentiate between β‐APP 695 and β‐APP 751 forms but does preferentially recognize β‐APP 751 complexed with a protease. Of the two sets of CSF samples tested, one set, obtained from living patients, gave a slightly lower level of β‐APP in AD and Parkinson's disease patients relative to controls, whereas the other set, composed of postmortem samples, showed no significant differences between the AD and control groups.